James Doroshow, MD
Enriched profileDirector, Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute; Senior Investigator, Developmental Therapeutics Branch, Center for Cancer Research · National Cancer Institute (NIH)
James Doroshow is Director, Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute; Senior Investigator, Developmental Therapeutics Branch, Center for Cancer Research at National Cancer Institute (NIH). OpenAlex indexes 1,455 publications with 38,626 citations (h-index 97); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
James H. Doroshow, MD, is Director, Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute. The public record shows 1,455 publications with 38,626 citations (h-index 97), centered on Cancer Genomics and Diagnostics, Radiomics and Machine Learning in Medical Imaging, Cancer therapeutics and mechanisms. It also documents an investigator role on 10 registered clinical trials, 1 NIH-funded awards (1999–2000).
- Most recent indexed publication: 2026 · Molecular cancer therapeutics
- Top research focus: Cancer Genomics and Diagnostics
- 10 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 36 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 428.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
Sponsor: National Cancer Institute (NCI)
- Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Sponsor: National Cancer Institute LAO
- Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
Sponsor: National Cancer Institute (NCI)
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 1999–2000 per NIH RePORTER. The latest:
- NADPH Oxidases as Novel Targets for Cancer Therapy
Division of Basic Sciences - Nci
FY2025$1,201,732ZIABC010677 - NADPH Oxidases as Novel Targets for Cancer Therapy
Division of Basic Sciences - Nci
FY2024$1,201,276ZIABC010677
Congress activity
Updated 27 Aug 2026
296 congress contributions (2004–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 4491: HDAC inhibitors induce NOX5 expression in human uveal melanoma cells in a Brd4-Sp1/Sp3-dependent manner.
AACR Annual Meeting
AACR2026Co-author - Abstract 6504: Combinatorial profiling of pidnarulex and other G-quadruplex ligands in 3D multicellular tumor spheroids
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Endosialin (CD248) Cancer Role and Therapeutics: 33 Years on.
Molecular cancer therapeutics
Review2026 - Perspectives From an Expert-Guided Discussion on Maximizing the Research Potential of Small Biopsy Tissue.
JCO precision oncology
Article2026 - Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.
Journal of clinical oncology
Clinical Trial2026 - Dynamic switching of apoptosis-modulating BIM heterodimers in response to BH3 mimetics in xenograft models of hematologic malignancies.
Molecular cancer therapeutics
Article2026 - Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults.
Journal of the National Cancer Institute
Article2026
Most-cited works
by citation count (OpenAlex)- 01Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors2,185 citations2012
- 02
- 03
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Facebook
m.facebook.com/story.php
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →m.facebook.com ↗ - Facebook
facebook.com/NCImedia/photos/dr-james-doroshow-deputy-director-the-nci-appeared-on-c-cpsans-washington-journal/10152788251470933
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗ - Instagram
instagram.com/p/C110-yNMMqP
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer.gov ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗
- Chairman
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center
2004verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacr.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- Author/contributor profile
OncLive (oncology news outlet)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.